Ramsay Hunt syndrome type II

related topics
{disease, patient, cell}
{island, water, area}
{line, north, south}

Ramsay Hunt syndrome (RHS) type 2 also known as herpes zoster oticus is a disorder that is caused by the reactivation of pre-existing herpes zoster virus in a nerve cell bundle in the head (the geniculate ganglion).[1] The neurons in this ganglion are responsible for the movements of facial muscles, the touch sensation of a part of ear and ear canal, the taste function of the frontal two-thirds of the tongue, and the moisturization of the eyes and the mouth. The syndrome specifically refers to the combination of this entity with weakness of the muscles activated by the facial nerve. In isolation the latter entity would be called Bell's Palsy.

Contents

Eponym

It is named for James Ramsay Hunt.[2][3]

Symptoms and signs

The symptoms and signs include acute facial nerve paralysis, pain in the ear, taste loss in the front two-thirds of the tongue, dry mouth and eyes, and eruption of a erythematous vesicular rash[4] in the ear canal, the tongue, and/or hard palate.

Since the vestibulocochlear nerve is in proximity to the geniculate ganglion, it may also be affected, and patients may also suffer from tinnitus, hearing loss, and vertigo.

Pathophysiology

RHS type 2 is essentially shingles of the geniculate ganglion. Briefly, the herpes zoster virus lies dormant in various nerve cells in the body, where it is kept in check by the patient's immune system. Given the opportunity, for example during an illness that suppresses the immune system, the virus is reactivated and travels to the end of the nerve cell, where it causes the symptoms described above.

Like shingles, however, lack of lesions does not definitely exclude the existence of a herpes infection. The virus can be detected, even before the eruption of vesicles, from the skin of the ear.[5]

Prognosis

The largest study on the treatment of RHS type 2 has shown that complete recovery can be achieved in 75% of patients if treatment with prednisone and acyclovir is started within the first 3 days of onset of facial paralysis.[6] Chances of complete recovery decrease as treatment is delayed. Studies have shown that half of all patients whose treatment was delayed had complete loss of response to facial nerve stimulation.

Full article ▸

related documents
Transient ischemic attack
Azotemia
Waterhouse-Friderichsen syndrome
Analgesic
Growth factor
Rift Valley fever
Heart disease
Shigella
Fallopian tube
Tricyclic antidepressant
Erythromycin
Wart
Melanocyte
Neurofibromatosis
Nose-picking
Placenta
Herd immunity
Rhinovirus
Human anatomy
Disease
Duodenum
Ulcerative colitis
Lemierre's syndrome
Capillary
Lithotriptor
Alpers' disease
Amoxicillin
Bioterrorism
John Cade
Shigellosis